RANOLAZINE ER (ranolazine)
ANTIANGINAL AND ANTI-ISCHEMIC AGENTS, NON-HEMODYNAMIC · PREVENTION OF ANGINAL PAIN ASSOCIATED WITH CORONARY ARTERY DISEASE
RADHA PHARMACEU
Drug class
Antianginal And Anti-Ischemic Agents, Non-Hemodynamic
Non-hemodynamic antianginal and anti-ischemic agents are cardiovascular medications that alleviate myocardial ischemia and angina pectoris without producing clinically significant changes in heart rate, systemic blood pressure, or vascular tone. Read more about Antianginal And Anti-Ischemic Agents, Non-Hemodynamic
29 drugs in this class 25 manufacturers
Drugs in Antianginal And Anti-Ischemic Agents, Non-Hemodynamic
RANOLAZINE ER (ranolazine)
ANTIANGINAL AND ANTI-ISCHEMIC AGENTS, NON-HEMODYNAMIC · PREVENTION OF ANGINAL PAIN ASSOCIATED WITH CORONARY ARTERY DISEASE
ZAMEER PHARMACE
Filter & compare in the drug finder →
Opens the drug finder with Antianginal And Anti-Ischemic Agents, Non-Hemodynamic preselected. Add indication or manufacturer filters there.
Non-hemodynamic antianginal and anti-ischemic agents are cardiovascular medications that alleviate myocardial ischemia and angina pectoris without producing clinically significant changes in heart rate, systemic blood pressure, or vascular tone.
Unlike conventional hemodynamic therapies such as beta-blockers, calcium channel blockers, and nitrates, these agents exert their cardioprotective actions via cellular or metabolic pathways, most notably through the selective inhibition of the late inward sodium current—which reduces intracellular calcium overload and myocardial wall tension—or via myocardial metabolic modulation.
They are primarily indicated for the management of chronic coronary syndromes and stable coronary artery disease, serving as useful monotherapy or add-on therapy, particularly in patients limited by hypotension or bradycardia.
-
openanesthesia.org
Non-hemodynamic antianginal and anti-ischemic agents are cardiovascular medications that alleviate myocardial ischemia and angina pectoris without producing clinically significant changes in heart rate, systemic blood pressure, or vascular tone They are primarily indicated for the management of chronic coronary syndromes and stable coronary artery disease, serving as useful monotherapy or add-on therapy, particularly in patients limited by hypotension or bradycardia
-
nih.gov
Non-hemodynamic antianginal and anti-ischemic agents are cardiovascular medications that alleviate myocardial ischemia and angina pectoris without producing clinically significant changes in heart rate, systemic blood pressure, or vascular tone
-
nih.gov
Unlike conventional hemodynamic therapies such as beta-blockers, calcium channel blockers, and nitrates, these agents exert their cardioprotective actions via cellular or metabolic pathways, most notably through the selective inhibition of the late inward sodium current—which reduces intracellular calcium overload and myocardial wall tension—or via myocardial metabolic modulation
-
nih.gov
Unlike conventional hemodynamic therapies such as beta-blockers, calcium channel blockers, and nitrates, these agents exert their cardioprotective actions via cellular or metabolic pathways, most notably through the selective inhibition of the late inward sodium current—which reduces intracellular calcium overload and myocardial wall tension—or via myocardial metabolic modulation
-
cardionerds.com
Unlike conventional hemodynamic therapies such as beta-blockers, calcium channel blockers, and nitrates, these agents exert their cardioprotective actions via cellular or metabolic pathways, most notably through the selective inhibition of the late inward sodium current—which reduces intracellular calcium overload and myocardial wall tension—or via myocardial metabolic modulation
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.